Clinical trials: Everyday Cognition
Non-Small Cell Lung Cancer NSCLC
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
- Trial name
- NCT02879617
- Testing
- durvalumab
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Schizophrenia
SB-773812 Administered In Adults With Schizophrenia
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo…
- Trial name
- NCT00259870
- Testing
- SB-773812, Olanzapine
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Sleep Disorders, Circadian Rhythm, Cognitive Dysfunction
Feasibility Study on the Use of Redormin®500 on Day-time Cognition
Randomized, double-blind, parallel groups, placebo-controlled, baseline/run-in period of 21 days followed by trial period of 21 days, digital phenotyping (sleep, cognitive/psychological parameters and HRV).
- Trial name
- NCT05684523
- Testing
- Valerian-Hop Extract
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Max Zeller Soehne AG
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer Disease, Dementia
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.
- Trial name
- NCT00105547
- Testing
- MPC-7869
- Where
- 132 sites in United States
- Volunteers
- 1,600 people
- Sponsor
- Myrexis Inc.
Stress
CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?
This clinical trial will investigate whether a powdered prebiotic fibre blend can improve perceived stress levels in healthy adults with mild-severe stress levels.
- Trial name
- CALM (NCT07201909)
- Testing
- Prebiotic fibre blend, Maltodextrin powder
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Myota GmbH
Cognitive Function, Memory
The Memory and Cognitive Performance Study
The primary purpose of this study is to evaluate the impact of a novel, neuro-protective and neuro-restorative dietary supplement (Braini®) on standardized memory and cognitive performance parameters.
- Conditions
- Cognitive Function, Memory, Brain Health
- Trial name
- NCT04025255
- Testing
- Braini
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vita Naturel, LLC
Epilepsy, Partial
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial…
- Trial name
- NCT00105040
- Testing
- Levetiracetam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- UCB Pharma
Mild to Moderate Alzheimer's Disease
A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease
This Phase 2a study will evaluate the safety and tolerability of GAL-101 in approximately 100 participants with mild to moderate Alzheimer's disease associated with amyloid-beta pathology.
- Trial name
- SAPHARY (NCT07789873)
- Testing
- GAL-101 Salt
- Volunteers
- 100 people
- Sponsor
- Galimedix Therapeutics Inc
Healthy
Feasibility & Characterization of Project: EVO Monitor Cognitive Measurements
This is an open-label study in adults to assess at-home Project: EVO Monitor measurements over repeat play cycles. The study has three arms:playing multiple times per day, once daily, and once weekly for 4 to 8 weeks.
- Trial name
- NCT02792296
- Testing
- Project: EVO Monitor
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Akili Interactive Labs, Inc.
Health Services Accessibility, Rural Health
Health Ahead Comparative Effectiveness Study
The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening…
- Conditions
- Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services
- Trial name
- HACE (NCT07669168)
- Testing
- AI-Assisted Screening Interpretation (AI Reads), Human-Only Screening Interpretation
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- William Brandenburg, MD
Non-Small Cell Lung Cancer
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess…
- Trial name
- NCT02944396
- Testing
- pemetrexed, nivolumab, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- AbbVie
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846868
- Testing
- Iclepertin
- Where
- 116 sites in United States, Australia and 15 more
- Volunteers
- 620 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846881
- Testing
- Iclepertin
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 611 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
This is a study in chronic stable Schizophrenia with the purpose to answer the question of whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well defined chronic stable patient population…
- Trial name
- NCT01730768
- Testing
- AQW051
- Where
- 13 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults
The primary objective of this study was to assess the efficacy and safety of Gingko biloba film-coated tablets in improving cognitive function and neuropsychological functioning of middle-aged cognitively intact adults.
- Trial name
- NCT02181972
- Testing
- Gingko biloba
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cognitive Impairment, Alzheimer Disease
A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers
This study explores the safety, pharmacodynamics and pharmacokinetics of THN201 a combination of donepezil and mefloquine to improve cognitive function in healthy male volunteers after impairment by a scopolamine challenge.
- Trial name
- NCT03698695
- Testing
- THN 201, Donepezil
- Where
- 7 sites in France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Theranexus
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease, Mild Cognitive Impairment
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved…
- Trial name
- NCT01099332
- Testing
- Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adeona Pharmaceuticals